Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network

Smith, Alexandra; Crouch, Simon; Lax, Stephanie J.; Li, J.; Painter, Daniel; Howell, Debra; Patmore, Russell; Jack, Andrew; Roman, Eve

doi:10.1038/bjc.2015.94

Cited by 338 publications

(308 citation statements)

References 49 publications

(58 reference statements)

Supporting

Mentioning

267

Contrasting

Unclassified

Order By: Relevance

“…This was in agreement with the study of Smith et al in which most B-cell malignancies subtypes were significantly higher in males than females [22]. Also, most of the patients in this research, excluding BL subgroup, were above 40 years old with mean age of 41.8 years.…”

Section: Discussionsupporting

confidence: 93%

Expression Signature of MicroRNA-155 and its Association with Response to Treatment within Different Subtypes of B-Cell Malignancies

Eldin¹,

Naem²,

Higazi³

et al. 2017

Biol Med (Aligarh)

View full text Add to dashboard Cite

Objectives: Emerging evidence suggests that microRNAs could serve as non-invasive biomarkers for cancer patients. However, they are mostly not fully investigated as biomarkers in the classification, progression and prognosis of different cancers. Our study was designed to explore the microRNA-155 (miR-155) expression levels in peripheral blood mononuclear cells (PBMCs) in patients with various subtypes of B-cell malignancies. Also, we aimed to correlate between miR-155 expression levels and the diverse clinico-pathologic features as well as the prognostic fate of these patients after treatment completion. Subjects and methods:Using whole blood samples from 53 patients with B-cell malignancies and 15 apparently healthy subjects, miR-155 was extracted and profiled by quantitative real-time PCR (RT-qPCR). The B-cell malignancies patients were including 22 diffuse large B-cell lymphoma (DLBCL), 15 chronic lymphocytic leukemia (CLL), 9 follicular lymphoma patients (FL) and 7 subjects with burkitt′s lymphoma (BL). The samples were withdrawn before starting chemotherapy in addition to after completing their therapeutic courses by 6 months. Subsequently, the patients were further sub-grouped into those with partial remission, complete remission, resistant disease and relapse. Results:We found that miR-155 expression levels differentiate lymphoma entities from normal subjects (p ≤ 0.001) and its expression fold changes distinguish B-cell lymphoma subtypes from each other's (p<0.05). In addition, miR-155 was significantly correlated with age and LDH levels. The receiver operating curve (ROC) was employed to identify the diagnostic outcomes of miR-155 in discriminating B-cell malignancies entities from each other's (AUC=0.957 for DLBCL vs. CLL+FL and AUC=1.000 for CLL vs. FL). Otherwise, when BL was versus healthy controls the AUC was equal to 0.552. As well, we demonstrated an association between elevated miR-155 expression levels and poor response to treatment with increased cases of relapse, partial remission or resistance to treatment. Conclusions:This study suggests that miR-155 has an expression profile that differs according to B-cell malignancies subtype. Besides, miR-155 expression levels may modulate the patient's response to treatment. These results support a role for miR-155 to provide helpful diagnostic/prognostic information in B-cell malignancies and may highlight novel pathways to be targeted for therapeutics in the future.

show abstract

Section: Discussionsupporting

confidence: 93%

Expression Signature of MicroRNA-155 and its Association with Response to Treatment within Different Subtypes of B-Cell Malignancies

Eldin¹,

Naem²,

Higazi³

et al. 2017

Biol Med (Aligarh)

View full text Add to dashboard Cite

show abstract

“…Zwar wurden in klinischen Studien, in denen kombinierte intensivierte Therapieelemente zur Anwendung kamen, Langzeit-Remissionen beobachtet, doch zeigen die unter realen Bedingungen gewonnenen Daten ein medianes Gesamtüberleben von weniger als 3 Jahren [58]. Selten oder nie wurde bei MCL-Zellen eine PD-L1-Positivität nachgewiesen [33,46].…”

Section: Mantelzelllymphomunclassified

Checkpoint-Inhibition bei Non-Hodgkin-Lymphom

Heß¹

2018

Kompass Onkol

View full text Add to dashboard Cite

Immer noch sterben Patienten an malignen Lymphomen, weshalb neue therapeutische Optionen weiterhin erforderlich sind. Um ungehindert wachsen und sich ausbreiten zu können, müssen Tumorzellen in der Lage sein, dem Immunsystem zu entgehen. Daher könnte die Verstärkung oder Wiederherstellung von Immuneffektormechanismen gegen maligne Zellen von großem Nutzen sein, wie dies beispielsweise für die allogene Transplantation gezeigt wurde. Fortschritte im Wissen über die Regulation der Aktivierung und Inhibition T-Zell-basierter Effektormechanismen haben zur Entwicklung von Arzneimitteln geführt, die in der Lage sind, spezifische Checkpoints dieses Systems zu verändern und auf diese Weise eine Immunreaktion gegen die Tumorzellen hervorzurufen. Angesichts des dramatischen Ansprechens bei Hodgkin-Lymphomen (HL) ist das Interesse, diese Arzneimittel auch bei Non-Hodgkin-Lymphomen (NHL) zu untersuchen, gestiegen. Die verfügbaren Daten unterstreichen das Potenzial von Checkpoint-Inhibitoren bei verschiedenen Lymphom-Entitäten, wie dem primären mediastinalen B-Zelllymphom (PMBCL) oder den Lymphomen des zentralen Nervensystems (ZNS), und es besteht die Hoffnung, dass ein Großteil der Patienten letztlich davon profitieren wird. Allerdings sind intensive Anstrengungen erforderlich, um optimale Screening-Instrumente, Kombinationen und Therapiesequenzen zu entwickeln und das gesamte Potenzial dieser neuen Klasse therapeutischer Wirkstoffe auszuloten. Übersetzung aus Oncol Res Treat 2017;40:662-672 (DOI:10.1159/000481888)

show abstract

“…Although long-term remissions have been observed within clinical trials combining intensive treatment elements, real-world data show a median overall survival of less than 3 years [58]. PD-L1 has never or rarely been shown to be positive in MCL cells [33,46].…”

Section: Mantle Cell Lymphomamentioning

confidence: 99%

Checkpoint Inhibition in Non-Hodgkin's Lymphoma

Heß

2017

Oncol Res Treat

View full text Add to dashboard Cite

As patients continue to die from malignant lymphoma, novel treatment options continue to be warranted. To successfully grow and spread, tumor cells need to escape the immune system; therefore, the augmentation or restoration of immune effectors against the malignant cell could be of great value, as shown, e.g., for allogeneic transplantation. A deepened understanding of the regulation of activation and inhibition of the T cell-based effector mechanisms has led to the development of drugs that are able to modify specific checkpoints of this system and thereby raise an immune response against tumor cells. With dramatic responses observed in Hodgkin's disease (HD), interest has risen to explore these drugs in non-Hodgkin's lymphoma (NHL). Available data underline the potential of checkpoint inhibitors in a variety of lymphoma entities, such as primary mediastinal B cell lymphoma (PMBCL) or central nervous system (CNS) lymphoma, and there is hope that a significant proportion of patients will finally benefit. However, intensive efforts are needed to develop optimal screening tools, combinations, and sequences to explore the full potential of these new classes of therapeutic agents.

show abstract

Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network

Cited by 338 publications

References 49 publications

Expression Signature of MicroRNA-155 and its Association with Response to Treatment within Different Subtypes of B-Cell Malignancies

Expression Signature of MicroRNA-155 and its Association with Response to Treatment within Different Subtypes of B-Cell Malignancies

Checkpoint-Inhibition bei Non-Hodgkin-Lymphom

Checkpoint Inhibition in Non-Hodgkin's Lymphoma

Contact Info

Product

Resources

About